Becker Lab

[Becker Lab @LevBecker]

@UCCancerCenter @UChicagoCCB @theNCI @PresCancerPanel @AACR @UofC Way to go Kasia!

[Becker Lab @LevBecker]

@jl_labelle @AkshaySharmaMD @JJ_boelens @jaybradner @MariaCancio3 @Seredev1 Congratulations James. Well deserved!

[Onchilles Pharma @onchilles]

In this Q&A with @DrugTargetRev, our cofounder Dr. Lev Becker shares more about how N17350 selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms.

https://t.co/olBshgdumy

[Onchilles Pharma @onchilles]

We will be presenting at #ImmunoSeries on our lead drug candidate, N17350, which is an emerging therapeutic modality that selectively kills any #cancer cells and stimulates anti-tumor immunity.

For the full @ImmunoOncConf agenda visit: https://t.co/nHw6Qc9LDW

[Onchilles Pharma @onchilles]

We will be presenting at #SITC23 our latest data on our lead drug candidate, N17350, showing a unique combination of potent and selective #cancer killing activity to eradicate #tumors independent of genetics or anatomical origin.

https://t.co/pvUMdERFk7

[UChicagoCancerCenter @UCCancerCenter]

The University of Chicago Medicine’s Cancer Program is one of the top-ranked specialties in the nation and the best in Illinois, according to the latest U.S. News & World Report.
https://t.co/1Nxqtr0DGE

[Becker Lab @LevBecker]

@BarbaraLKee @japizsaab @Muir_Lab Congratulations Juan and Alex. Beautiful work!

[Onchilles Pharma @onchilles]

We’re excited to present today at #AACR23 new preclinical data for our lead candidate N17350, which possesses unique therapeutic characteristics and may be a major new treatment modality in #immunooncology.

See the press release & poster here: https://t.co/Rezp8qgnYN

[Dr. Michele A. Basso @MicheleABasso1]

Check out 60 minutes tonight. Thanks to hardworking neuroscientists, amazing patients and especially monkeys, BCI is helping people every day. @Wa_NPRC @slimanjbensmaia https://t.co/DeN1MbuuM9

[Becker Lab @LevBecker]

@DrTonyLetai Ct26 responds well, 4T1 does not.

[Becker Lab @LevBecker]

Excited to be attending the 2023 Weinman Symposium in Honolulu. One of my favourite conferences in terms of speakers, venue, and organisation. Aloha. https://t.co/INkkaFYDzl

[Onchilles Pharma @onchilles]

Today we disclosed our 1st drug development candidate, N17350, a first-in-class biologic to leverage #neutrophil biology and broadly treat #cancer. We also expanded our platform to design new therapeutics to modulate M2-like tumor-associated #macrophages.

https://t.co/K1ej0hi7YK

[Becker Lab @LevBecker]

@UCCancerCenter @UChicago @UChicagoPME Congratulations guys. Excellent work!

[Becker Lab @LevBecker]

@ElfLabUChicago @BCD_AACR Congrats Shannon and team.

[Becker Lab @LevBecker]

@GWIntegrative @GWSMHS @GW_MFA Excited to participate in this wonderful seminar series.

[Becker Lab @LevBecker]

@DavanzoGG Congratulations Gus!!!!!

[Macleod Lab - University of Chicago @LabMacleod]

Tenure Track Assistant Professorship in the Ben May Department for Cancer Research - looking for talented applicants focused on Mechanistic Aspects of Prostate Cancer or Related Areas. EOE/Vet/Disability. Apply here:
https://t.co/aEAOsJCNDo

[Becker Lab @LevBecker]

Excited to be participating in @AIC2021 tomorrow. My first in-person conference in 2 years. Looking forward to (safely) interacting with a fantastic line up of immunologists and trainees.
https://t.co/U02Ev5Y2JY

[Becker Lab @LevBecker]

Excited to share a collaborative paper with @KrishnanYamuna in @NatureNano. Read on to see how we identified a new #innateimmune defect in #cancer and used #DNAnanotechnology to correct it. Congratulations to @PurrChangC, @deeyakc, and all coauthors. https://t.co/N3lEYGPHL8

[Onchilles Pharma @onchilles]

Today we welcome Chang Cui, Ph.D., to the team! Prior to joining us, @PurrChangC advanced foundational research in @LevBecker’s lab of a novel #neutrophilpathway with broad #anticancer potential for new #cancer #immunotherapy treatments.